{
    "id": 21879,
    "fullName": "SMARCA4 mutant",
    "impact": "unknown",
    "proteinEffect": "unknown",
    "geneVariantDescriptions": [
        {
            "description": "SMARCA4 mutant indicates an unspecified mutation in the SMARCA4 gene.",
            "references": [
                {
                    "id": 275,
                    "pubMedId": null,
                    "title": "External Reference Not Available (N/A)",
                    "url": "https://ckb.jax.org/about/glossaryOfTerms"
                }
            ]
        }
    ],
    "type": "category",
    "gene": {
        "id": 6597,
        "geneSymbol": "SMARCA4",
        "terms": [
            "SMARCA4",
            "BAF190",
            "BAF190A",
            "BRG1",
            "CSS4",
            "hSNF2b",
            "MRD16",
            "RTPS2",
            "SNF2",
            "SNF2-beta",
            "SNF2L4",
            "SNF2LB",
            "SWI2"
        ]
    },
    "variant": "mutant",
    "createDate": "04/29/2016",
    "updateDate": "05/15/2018",
    "referenceTranscriptCoordinates": null,
    "partnerGenes": [
        
    ],
    "evidence": [
        {
            "id": 15945,
            "approvalStatus": "Preclinical - Cell line xenograft",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, Iclusig (ponatinib) treatment of small cell carcinoma of the ovary, hypercalcemic type (SCCOHT) cell lines and xenografts with mutant SMARCA4 resulted in decreased cell viability and tumor volume (PMID: 29440177).",
            "molecularProfile": {
                "id": 22426,
                "profileName": "SMARCA4 mutant"
            },
            "therapy": {
                "id": 877,
                "therapyName": "Ponatinib",
                "synonyms": null
            },
            "indication": {
                "id": 7651,
                "name": "small-cell carcinoma of the ovary of hypercalcemic type",
                "source": "DOID"
            },
            "responseType": "sensitive",
            "references": [
                {
                    "id": 14061,
                    "pubMedId": 29440177,
                    "title": "Ponatinib Shows Potent Antitumor Activity in Small Cell Carcinoma of the Ovary Hypercalcemic Type (SCCOHT) through Multikinase Inhibition.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/29440177"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 16818,
            "approvalStatus": "Phase II",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a Phase II trial (AIM), distinct molecular profiles were identified in mantle cell lymphoma patients responded to Imbruvica (ibrutinib) and Venclexta (venetoclax) combination therapy compared to those did not respond, with all patients harboring mutations in NSD2 (n=4), UBR5 (n=3), KMT2D (n=3), and 12 of 13 patients harboring mutations in ATM responded to the therapy, while SMARCA4 (n=4), CCND1 (n=2), and NOTCH1 (n=3) alterations were exclusively observed in nonresponders (PMID: 30455436; NCT02471391).",
            "molecularProfile": {
                "id": 22426,
                "profileName": "SMARCA4 mutant"
            },
            "therapy": {
                "id": 3392,
                "therapyName": "Ibrutinib + Venetoclax",
                "synonyms": null
            },
            "indication": {
                "id": 50746,
                "name": "mantle cell lymphoma",
                "source": "DOID"
            },
            "responseType": "predicted - resistant",
            "references": [
                {
                    "id": 14918,
                    "pubMedId": 30455436,
                    "title": "Dynamic molecular monitoring reveals that SWI-SNF mutations mediate resistance to ibrutinib plus venetoclax in mantle cell lymphoma.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/30455436"
                }
            ],
            "ampCapAscoEvidenceLevel": "B",
            "ampCapAscoInferredTier": "I"
        },
        {
            "id": 9881,
            "approvalStatus": "Preclinical - Cell culture",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, a non-small cell lung cancer cell line harboring a SMARCA4 mutation demonstrated sensitivity to Tozasertib (VX-680) in culture (Cancer Res July 15 2016 (76) (14 Supplement) LB-318).",
            "molecularProfile": {
                "id": 22426,
                "profileName": "SMARCA4 mutant"
            },
            "therapy": {
                "id": 943,
                "therapyName": "Tozasertib",
                "synonyms": null
            },
            "indication": {
                "id": 3908,
                "name": "lung non-small cell carcinoma",
                "source": "DOID"
            },
            "responseType": "predicted - sensitive",
            "references": [
                {
                    "id": 7735,
                    "pubMedId": null,
                    "title": "Abstract LB-318: SMARCA4-inactivating mutations increase sensitivity to Aurora kinase A-targeted therapies in non-small cell lung cancers (NSCLCs)",
                    "url": "http://cancerres.aacrjournals.org/content/76/14_Supplement/LB-318.short"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6619,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human adrenal gland cancer cells harboring SMARCA4 and TP53 mutations were resistant to LY3009120 mediated growth inhibition in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23647,
                "profileName": "SMARCA4 mut TP53 mut"
            },
            "therapy": {
                "id": 3268,
                "therapyName": "LY3009120",
                "synonyms": null
            },
            "indication": {
                "id": 3953,
                "name": "adrenal gland cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6618,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human adrenal gland cancer cells harboring SMARCA4 and TP53 mutations were resistant to Tafinlar (dabrafenib) mediated growth inhibition in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23647,
                "profileName": "SMARCA4 mut TP53 mut"
            },
            "therapy": {
                "id": 3,
                "therapyName": "Dabrafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3953,
                "name": "adrenal gland cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        },
        {
            "id": 6620,
            "approvalStatus": "Preclinical",
            "evidenceType": "Actionable",
            "efficacyEvidence": "In a preclinical study, human adrenal gland cancer cells harboring SMARCA4 and TP53 mutations were resistant to Zelboraf (vemurafenib) mediated growth inhibition in culture (PMID: 26343583).",
            "molecularProfile": {
                "id": 23647,
                "profileName": "SMARCA4 mut TP53 mut"
            },
            "therapy": {
                "id": 342,
                "therapyName": "Vemurafenib",
                "synonyms": null
            },
            "indication": {
                "id": 3953,
                "name": "adrenal gland cancer",
                "source": "DOID"
            },
            "responseType": "resistant",
            "references": [
                {
                    "id": 5709,
                    "pubMedId": 26343583,
                    "title": "Inhibition of RAF Isoforms and Active Dimers by LY3009120 Leads to Anti-tumor Activities in RAS or BRAF Mutant Cancers.",
                    "url": "http://www.ncbi.nlm.nih.gov/pubmed/26343583"
                }
            ],
            "ampCapAscoEvidenceLevel": "D",
            "ampCapAscoInferredTier": "II"
        }
    ],
    "molecularProfiles": [
        {
            "id": 22426,
            "profileName": "SMARCA4 mutant",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 23647,
            "profileName": "SMARCA4 mut TP53 mut",
            "profileTreatmentApproaches": [
                
            ]
        },
        {
            "id": 32246,
            "profileName": "SMARCA4 mut TP53 wild-type",
            "profileTreatmentApproaches": [
                
            ]
        }
    ],
    "allTranscriptCoordinates": [
        
    ]
}